Exabis Library
Welcome to the e-CCO Library!
OP40: Analysis of clinical features associated with favourable outcomes from ustekinumab treat-to-target strategy in Crohn’s Disease patients in the STARDUST trial
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
OP40: Efficacy of risankizumab induction and maintenance therapy by baseline Crohn’s Disease location: Post hoc analysis of the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
OP40: PRA023 Demonstrated Efficacy and Favorable Safety as Induction Therapy for Moderately to Severely Active UC: Phase 2 ARTEMIS-UC Study Results
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
P001 The novel DYRK1a inhibitor VRN024219 alleviates disease severity on the IBD mouse models by modulating T-cell differentiation
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P001: Comparison of in vivo T cell homing to the inflamed gut with the etrolizumab surrogate antibody FIB504 and vedolizumab in a humanised mouse model
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P001: Establishment of in vitro human model for ulcerative colitis by using human colon organoid culture
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P001: Immune checkpoint inhibitor-induced colitis is mediated by polyfunctional lymphocytes and is dependent on the IL23/IFNg axis
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P001: Multi-omic data integration assisted identification of molecular features contributing to disease heterogeneity in Crohn's disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P001: Obefazimod upregulates miR-124 and downregulates the expression of some cytokines in blood and rectal biopsies of patients with moderate-to-severe ulcerative colitis.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
P001: Succinate, a gut microbiota-derived metabolite, modulates the inflammatory status of the creeping fat in Crohn’s disease.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P001: The biomarker profile of PTG-200, an oral peptide antagonist of IL-23 receptor, tracks with efficacy in a preclinical model of IBD
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P002 Specific genome editing to model hypermethylation of the SP140 gene that associates to Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P002: Beneficial effects of blocking EphBs-ephrinBs forward signalling in a murine Crohn’s sisease (CD) model
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P002: Endoscopic placement of a drug-eluting platform with monoclonal antibodies in an animal model of experimental colitis by TNBS: effect on disease outcome and anti-drug antibodies (ADA’s) formation
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P002: Epithelial to mesenchymal transition is a hallmark of fibrostenosing Crohn’s disease and is associated with down regulation of the miR-200 family
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P002: Exclusive Enteral Nutrition, the gut microbiome and corticosteroid response in patients with acute severe colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
P002: Glial cell line-Derived Neurotrophic Factor (GDNF) improves intestinal wound healing – A new target for IBD treatment?
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P002: Inhibition of Axl signaling by BGB324 reduces fibrogenesis in human intestinal cells and human intestinal organoids
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P002: Methodological development of single-cell phenotyping and spatial analysis of intestinal leukocyte, stromal and epithelial cell populations in inflammatory bowel disease formalin fixed paraffin embedded tissue by Hyperion imaging mass cytometry
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P003 Metabolomics for improved patient stratification in inflammatory bowel disease: Characterisation of the ulcerative colitis metabolome
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM